Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

28

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Bacterial 70S ribosome

26

Bacterial dihydropteroate synthase

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

28

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1952

26

1961

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Acne

26

Bacterial endocarditis

26

Diphtheria

26

Erythrasma

26

Listeriosis

26

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

28

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

28

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Eli Lilly

26

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

28

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

28

FDA UNII

28

PUBCHEM

28

EPA CompTox

19

SMS_ID

17

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

2

DERMATOLOGICALS

1

SENSORY ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIBACTERIALS FOR SYSTEMIC USE

2

ANTI-ACNE PREPARATIONS

1

ANTIMYCOBACTERIALS

1

OPHTHALMOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTI-ACNE PREPARATIONS FOR TOPICAL USE

1

ANTIINFECTIVES

1

DRUGS FOR TREATMENT OF TUBERCULOSIS

1

MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS

1

SULFONAMIDES AND TRIMETHOPRIM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antibiotics

1

Antiinfectives for treatment of acne

1

Combinations of drugs for treatment of tuberculosis

1

Combinations of sulfonamides and trimethoprim, incl. derivatives

1

Intermediate-acting sulfonamides

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

26

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 28 results

First page disabled
Previous page disabled
1
Next page
Next page

SULFAMETHOXAZOLE

JE42381TNV

Export Data
Search for Structure

Status:

US Approved Rx (2010)

First approved in 1961

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Bacterial dihydropteroate synthase

Conditions:

Pneumocystis jiroveci pneumonia

Urinary tract infections

Travelers’ diarrhea

Acute exacerbations of chronic bronchitis in adults

Acute otitis media

Sulfamethoxazole is a synthetic antibacterial drug,which is used in combination with trimethoprim (Bactrim, Septra) for the treatment or prevention of infections that are proven or strongly suspected to be caused by bacteria. Sulfamethoxazole acts by...

inhibiting folic acid synthesis via enzyme called dihydropteroate synthase.

Erythromycin

63937KV33D

Export Data
Search for Structure

Status:

US Approved Rx (1972)

First approved in 1952

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial 70S ribosome

Bacterial 70S ribosome

Bacterial 70S ribosome

Conditions:

Respiratory tract infections

Skin and skin structure infections

Skin and skin structure infections

Respiratory tract infections

Bacterial endocarditis

Staphylococcal dermatitis

Erythromycin cyclocarbonate (Davercin) is a first generation semi-synthetic erythromycin. It is active against Gram-positive and some Gram-negative microorganisms. Davercin shows comparable or better in vitro potency, low host toxicity and improved p...

harmacokinetics compared with erythromycin. It is approved for the treatment of acne, atypical pneumonia (caused by Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila), whooping cough (treatment and prevention), urethritis (caused by Ureaplasma urealyticum and Chlamydia trachomatis), gastrointestinal infection caused by Campylobacter spp., short-term infections of the skin and soft tissues (e.g. acne, staphylococcal dermatitis). In streptococcal infections, diphtheria, gonorrhea, early syphilis in patients who are allergic to penicillin, and in the prevention of bacterial endocarditis before the planned dental procedures. Adverse effects are: nausea, vomiting, abdominal pain, diarrhea, skin allergic reactions.

SULFAMETHOXAZOLE SODIUM

PJ0X8H59AI

Export Data
Search for Structure

Status:

US Approved Rx (2010)

First approved in 1961

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Bacterial dihydropteroate synthase

Conditions:

Pneumocystis jiroveci pneumonia

Urinary tract infections

Travelers’ diarrhea

Acute exacerbations of chronic bronchitis in adults

Acute otitis media

Sulfamethoxazole is a synthetic antibacterial drug,which is used in combination with trimethoprim (Bactrim, Septra) for the treatment or prevention of infections that are proven or strongly suspected to be caused by bacteria. Sulfamethoxazole acts by...

inhibiting folic acid synthesis via enzyme called dihydropteroate synthase.

ERYTHROMYCIN ACISTRATE

6383U5A1KE

Export Data
Search for Structure

Status:

US Approved Rx (1972)

First approved in 1952

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial 70S ribosome

Bacterial 70S ribosome

Bacterial 70S ribosome

Conditions:

Respiratory tract infections

Skin and skin structure infections

Skin and skin structure infections

Respiratory tract infections

Bacterial endocarditis

Staphylococcal dermatitis

Erythromycin cyclocarbonate (Davercin) is a first generation semi-synthetic erythromycin. It is active against Gram-positive and some Gram-negative microorganisms. Davercin shows comparable or better in vitro potency, low host toxicity and improved p...

harmacokinetics compared with erythromycin. It is approved for the treatment of acne, atypical pneumonia (caused by Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila), whooping cough (treatment and prevention), urethritis (caused by Ureaplasma urealyticum and Chlamydia trachomatis), gastrointestinal infection caused by Campylobacter spp., short-term infections of the skin and soft tissues (e.g. acne, staphylococcal dermatitis). In streptococcal infections, diphtheria, gonorrhea, early syphilis in patients who are allergic to penicillin, and in the prevention of bacterial endocarditis before the planned dental procedures. Adverse effects are: nausea, vomiting, abdominal pain, diarrhea, skin allergic reactions.

ERYTHROMYCIN LAURYLSULFATE

U6A4H0OY0H

Export Data
Search for Structure

Status:

US Approved Rx (1972)

First approved in 1952

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial 70S ribosome

Bacterial 70S ribosome

Bacterial 70S ribosome

Conditions:

Respiratory tract infections

Skin and skin structure infections

Skin and skin structure infections

Respiratory tract infections

Bacterial endocarditis

Staphylococcal dermatitis

Erythromycin cyclocarbonate (Davercin) is a first generation semi-synthetic erythromycin. It is active against Gram-positive and some Gram-negative microorganisms. Davercin shows comparable or better in vitro potency, low host toxicity and improved p...

harmacokinetics compared with erythromycin. It is approved for the treatment of acne, atypical pneumonia (caused by Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila), whooping cough (treatment and prevention), urethritis (caused by Ureaplasma urealyticum and Chlamydia trachomatis), gastrointestinal infection caused by Campylobacter spp., short-term infections of the skin and soft tissues (e.g. acne, staphylococcal dermatitis). In streptococcal infections, diphtheria, gonorrhea, early syphilis in patients who are allergic to penicillin, and in the prevention of bacterial endocarditis before the planned dental procedures. Adverse effects are: nausea, vomiting, abdominal pain, diarrhea, skin allergic reactions.

ERYTHROMYCIN PALMITATE

6Z8MKY9M4G

Export Data
Search for Structure

Status:

US Approved Rx (1972)

First approved in 1952

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial 70S ribosome

Bacterial 70S ribosome

Bacterial 70S ribosome

Conditions:

Respiratory tract infections

Skin and skin structure infections

Skin and skin structure infections

Respiratory tract infections

Bacterial endocarditis

Staphylococcal dermatitis

Erythromycin cyclocarbonate (Davercin) is a first generation semi-synthetic erythromycin. It is active against Gram-positive and some Gram-negative microorganisms. Davercin shows comparable or better in vitro potency, low host toxicity and improved p...

harmacokinetics compared with erythromycin. It is approved for the treatment of acne, atypical pneumonia (caused by Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila), whooping cough (treatment and prevention), urethritis (caused by Ureaplasma urealyticum and Chlamydia trachomatis), gastrointestinal infection caused by Campylobacter spp., short-term infections of the skin and soft tissues (e.g. acne, staphylococcal dermatitis). In streptococcal infections, diphtheria, gonorrhea, early syphilis in patients who are allergic to penicillin, and in the prevention of bacterial endocarditis before the planned dental procedures. Adverse effects are: nausea, vomiting, abdominal pain, diarrhea, skin allergic reactions.

ERYTHROMYCIN SALNACEDIN ANHYDROUS

A45292J59T

Export Data
Search for Structure

Status:

US Approved Rx (1972)

First approved in 1952

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial 70S ribosome

Bacterial 70S ribosome

Bacterial 70S ribosome

Conditions:

Respiratory tract infections

Skin and skin structure infections

Skin and skin structure infections

Respiratory tract infections

Bacterial endocarditis

Staphylococcal dermatitis

Erythromycin cyclocarbonate (Davercin) is a first generation semi-synthetic erythromycin. It is active against Gram-positive and some Gram-negative microorganisms. Davercin shows comparable or better in vitro potency, low host toxicity and improved p...

harmacokinetics compared with erythromycin. It is approved for the treatment of acne, atypical pneumonia (caused by Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila), whooping cough (treatment and prevention), urethritis (caused by Ureaplasma urealyticum and Chlamydia trachomatis), gastrointestinal infection caused by Campylobacter spp., short-term infections of the skin and soft tissues (e.g. acne, staphylococcal dermatitis). In streptococcal infections, diphtheria, gonorrhea, early syphilis in patients who are allergic to penicillin, and in the prevention of bacterial endocarditis before the planned dental procedures. Adverse effects are: nausea, vomiting, abdominal pain, diarrhea, skin allergic reactions.

ERYTHROMYCIN CYCLOCARBONATE

4H3125L82R

Export Data
Search for Structure

Status:

US Approved Rx (1972)

First approved in 1952

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial 70S ribosome

Bacterial 70S ribosome

Bacterial 70S ribosome

Conditions:

Respiratory tract infections

Skin and skin structure infections

Skin and skin structure infections

Respiratory tract infections

Bacterial endocarditis

Staphylococcal dermatitis

Erythromycin cyclocarbonate (Davercin) is a first generation semi-synthetic erythromycin. It is active against Gram-positive and some Gram-negative microorganisms. Davercin shows comparable or better in vitro potency, low host toxicity and improved p...

harmacokinetics compared with erythromycin. It is approved for the treatment of acne, atypical pneumonia (caused by Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila), whooping cough (treatment and prevention), urethritis (caused by Ureaplasma urealyticum and Chlamydia trachomatis), gastrointestinal infection caused by Campylobacter spp., short-term infections of the skin and soft tissues (e.g. acne, staphylococcal dermatitis). In streptococcal infections, diphtheria, gonorrhea, early syphilis in patients who are allergic to penicillin, and in the prevention of bacterial endocarditis before the planned dental procedures. Adverse effects are: nausea, vomiting, abdominal pain, diarrhea, skin allergic reactions.

ERYTHROMYCIN SALNACEDIN

VMA8F29A76

Export Data
Search for Structure

Status:

US Approved Rx (1972)

First approved in 1952

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial 70S ribosome

Bacterial 70S ribosome

Bacterial 70S ribosome

Conditions:

Respiratory tract infections

Skin and skin structure infections

Skin and skin structure infections

Respiratory tract infections

Bacterial endocarditis

Staphylococcal dermatitis

Erythromycin cyclocarbonate (Davercin) is a first generation semi-synthetic erythromycin. It is active against Gram-positive and some Gram-negative microorganisms. Davercin shows comparable or better in vitro potency, low host toxicity and improved p...

harmacokinetics compared with erythromycin. It is approved for the treatment of acne, atypical pneumonia (caused by Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila), whooping cough (treatment and prevention), urethritis (caused by Ureaplasma urealyticum and Chlamydia trachomatis), gastrointestinal infection caused by Campylobacter spp., short-term infections of the skin and soft tissues (e.g. acne, staphylococcal dermatitis). In streptococcal infections, diphtheria, gonorrhea, early syphilis in patients who are allergic to penicillin, and in the prevention of bacterial endocarditis before the planned dental procedures. Adverse effects are: nausea, vomiting, abdominal pain, diarrhea, skin allergic reactions.

ERYTHROMYCIN PHOSPHATE

I8T8KU14X7

Export Data
Search for Structure

Status:

US Approved Rx (1972)

First approved in 1952

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial 70S ribosome

Bacterial 70S ribosome

Bacterial 70S ribosome

Conditions:

Respiratory tract infections

Skin and skin structure infections

Skin and skin structure infections

Respiratory tract infections

Bacterial endocarditis

Staphylococcal dermatitis

Erythromycin cyclocarbonate (Davercin) is a first generation semi-synthetic erythromycin. It is active against Gram-positive and some Gram-negative microorganisms. Davercin shows comparable or better in vitro potency, low host toxicity and improved p...

harmacokinetics compared with erythromycin. It is approved for the treatment of acne, atypical pneumonia (caused by Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila), whooping cough (treatment and prevention), urethritis (caused by Ureaplasma urealyticum and Chlamydia trachomatis), gastrointestinal infection caused by Campylobacter spp., short-term infections of the skin and soft tissues (e.g. acne, staphylococcal dermatitis). In streptococcal infections, diphtheria, gonorrhea, early syphilis in patients who are allergic to penicillin, and in the prevention of bacterial endocarditis before the planned dental procedures. Adverse effects are: nausea, vomiting, abdominal pain, diarrhea, skin allergic reactions.

Showing 1 - 10 of 28 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1